Motixafortide
FDA-approved CXCR4 medicines that block a signal for stem-cell mobilization (Aphexda).
What it's for
FDA-approved CXCR4 medicines that block a signal for stem-cell mobilization (Aphexda).
What it's for
Motixafortide is a lab-made peptide medicines that block a signal of the chemokine receptors (lock-and-key landing spots on cells) CXCR4. Used with G-CSF to mobilize hematopoietic stem cells for collection in multiple myeloma patients preparing for autologous transplant.
What it does for the body
Used with G-CSF to mobilize hematopoietic stem cells for collection in multiple myeloma patients preparing for autologous transplant. People often hear about it through clinics, forums, or news — this guide sticks to what published research and regulators actually support.
What it targets
Blocking CXCR4–CXCL12 retention signals releases stem cells into peripheral blood. Researchers map these ideas in cells and animals first; human proof has to clear a higher bar.
Research context
Bottom line for readers: Motixafortide has a defined FDA-approved story. Use the citations tab to open labels and trial registries, and treat anything beyond the label as unverified.
Studied for (literature interest)
- Heart research interest (educational tag)
Cautions (educational)
- Educational only — not medical advice.
- DrPep does not offer medical consultations, dosing guidance, suppliers, or peptide sales.
Citations / starters
- FDA search: Motixafortide — FDA.gov search
- ClinicalTrials.gov search: Motixafortide — U.S. clinical trials registry
- Drugs@FDA search: Motixafortide — FDA drug database (if approved)
- PubMed search: Motixafortide — NCBI PubMed
- PubMed Central search: Motixafortide — NCBI PMC